Literature DB >> 15389816

Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III).

Sabine Rohrmann1, Angelo M De Marzo, Ellen Smit, Edward Giovannucci, Elizabeth A Platz.   

Abstract

BACKGROUND: Inflammatory infiltrates are frequently found in and around nodules in benign prostate hyperplasia (BPH). We examined cross-sectionally the association of serum C-reactive protein concentration, a non-specific marker of inflammation, and lower urinary tract symptoms (LUTS), suggestive of BPH.
METHODS: We included 2,337 men, 60 years and older, who participated in the Third National Health and Examination Survey (NHANES III) between 1988 and 1994. As part of NHANES III, serum C-reactive protein concentration was measured and men reported whether they currently experienced nocturia, incomplete emptying, hesitancy, or weak stream as well as whether they had had non-cancer prostate surgery in the past. All results were weighted to account for sampling probability in NHANES III.
RESULTS: Age-adjusted and weighted mean serum C-reactive protein concentration was 0.32 mg/dl in men without symptoms and without surgery, 0.35 mg/dl in men with three or four symptoms (P = 0.06), and 0.36 mg/dl in men with one or two symptoms (P = 0.06). After adjusting for age and race and excluding men with an acute infection, men with a C-reactive protein concentration above the limit of detection (>0.30 mg/dl) were 1.47 times (95% CI 0.87-2.50) more likely to have three or four symptoms than men with a C-reactive protein concentration below the detection limit, although the association was not statistically significant. The association was not attenuated after adjusting for the metabolic syndrome, but was attenuated after excluding men with metabolic syndrome.
CONCLUSIONS: These results suggest that elevated circulating C-reactive protein concentration might be an indicator of intraprostatic inflammation in symptomatic BPH. The presence of the metabolic syndrome might be a mediator of this association. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15389816     DOI: 10.1002/pros.20110

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  36 in total

Review 1.  Lifestyle and lower urinary tract symptoms: what is the correlation in men?

Authors:  Pao-Hwa Lin; Stephen J Freedland
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

2.  Best of the 2006 AUA Annual Meeting: Highlights from the 2006 Annual Meeting of the American Urological Association, May 20-25, 2006, Atlanta, GA.

Authors: 
Journal:  Rev Urol       Date:  2006

3.  Nutraceuticals in Prostate Disease: The Urologist's Role.

Authors:  J Curtis Nickel; Daniel Shoskes; Claus G Roehrborn; Mark Moyad
Journal:  Rev Urol       Date:  2008

4.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

5.  Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.

Authors:  Opal Lin-Tsai; Peter E Clark; Nicole L Miller; Jay H Fowke; Omar Hameed; Simon W Hayward; Douglas W Strand
Journal:  Prostate       Date:  2014-02-05       Impact factor: 4.104

Review 6.  Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Sanjay Kasturi; Shane Russell; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 7.  Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia.

Authors:  LaTayia Aaron; Omar E Franco; Simon W Hayward
Journal:  Urol Clin North Am       Date:  2016-08       Impact factor: 2.241

8.  The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome.

Authors:  Xiangyu Zhang; Xiaofang Zeng; Lini Dong; Xiaokun Zhao; Xiaobing Qu
Journal:  World J Urol       Date:  2015-04-08       Impact factor: 4.226

Review 9.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

Review 10.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.